We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, ...

The market expects Regeneron (REGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 13th annual Regeneron Prize for Creative Innovation (the “Regeneron Prize”), which recognizes and rewards outstanding ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN stock is upgraded to buy.

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

Buying $1000 In REGN: If an investor had bought $1000 of REGN stock 20 years ago, it would be worth $57,109.53 today based on a price of $563.10 for REGN at the time of writing.

Me’s privacy ombudsman secured court approval to retain WilmerHale in the DNA testing company’s Chapter 11 case despite an ...

Shares of Regeneron Pharmaceuticals Inc. REGN slid 1.35% to $564.64 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.07% to ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

Regeneron Pharmaceuticals demonstrates a stronger financial position compared to its top 4 peers in the sector. With a lower debt-to-equity ratio of 0.1, ...

Regeneron Genetics Center (RGC) was founded in 2013 to harness the power of human genetics. “In the decade since its inception, the work done at RGC has provided us with one of the world’s ...

Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.